Text Size

The Prevalence of Sympathetic Overactivity in Primary Hypertensive Patients. (SORT)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT01295021
First received: February 3, 2011
Last updated: February 20, 2013
Last verified: February 2013
History of Changes

February 3, 2011
February 20, 2013
February 2011
February 2012   (final data collection date for primary outcome measure)
Prevalence of SO in newly diagnosed hypertensive patients [ Time Frame: Visit 1-3: heart rate & Blood pressure, treatment presribed by physician. The interval between visit 1 and visit 2 is upto 4 weeks and interval between visit 2 & visit 3 is upto 4 weeks depending on Investigators discretion. ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01295021 on ClinicalTrials.gov Archive Site
  • Association of SO and heart rate. [ Time Frame: Visits 1-3 ] [ Designated as safety issue: No ]
  • Subjective symptoms noticed by the doctor. [ Time Frame: 1st visit ] [ Designated as safety issue: No ]
  • To record the drugs used in the treatment of patients diagnosed with hypertension. [ Time Frame: Visits 1-3 ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
The Prevalence of Sympathetic Overactivity in Primary Hypertensive Patients.
A Non Interventional, Cross Sectional, Study on the Prevalence of Sympathetic Overactivity in Hypertensive Patients.

The purpose of this NIS is to assess the prevalence of sympathetic overactivity in patients with newly diagnosed essential hypertension.

MC MD
Observational
Observational Model: Cohort
Time Perspective: Cross-Sectional
Not Provided
Not Provided
Non-Probability Sample

Primary hypertensive patients
Essential Hypertension
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
5400
February 2012
February 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Newly diagnosed essential hypertension patients will be eligible for the study.
  • Average of two or more systolic BP readings ≥ 140mmHg or diastolic BP readings ≥ 90mmHg

Exclusion Criteria:

  • History of coronary artery disease
  • History of diabetes
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
India
 
NCT01295021
NIS-CIN-DUM-2010/2
No
AstraZeneca
AstraZeneca
Not Provided
Principal Investigator: Dr T.N.C. Padmanabhan Dr. Padmanabhan Heart Clinic
AstraZeneca
February 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP